3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Blast Crisis
1
Interventions
Fluorouracil
11
Leucovorin
10
Oxaliplatin
9
Bevacizumab
6
Irinotecan
5
Capecitabine
3
regorafenib
2
aflibercept
2
Folfox protocol
2
Exercise
2
Chemotherapy, Adjuvant
2
Cetuximab
2
Biopsy
2
Atorvastatin
2
tucatinib
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
sulindac sulfone
1
sargramostim
1
retrovector encoding mutant anti-cyclin G1
1
poly ICLC
1
pidilizumab
1
pembrolizumab
1
p53 peptide 264-272, human
1
nilotinib
1
monalizumab
1
lonafarnib
1
irofulven
1
infigratinib
1
grp protein, Drosophila
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Colonic Neoplasms
×
nilotinib
×
Clear all
NCT02774512
2017-10-06
ZAK-0
Institut Bergonié
Phase EARLY_PHASE1
Withdrawn